These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. First-episode schizophrenia: the importance of early intervention and subjective tolerability. Kasper S J Clin Psychiatry; 1999; 60 Suppl 23():5-9. PubMed ID: 10625193 [TBL] [Abstract][Full Text] [Related]
3. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone. Kopala LC; Fredrikson D; Good KP; Honer WG Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777 [No Abstract] [Full Text] [Related]
4. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?]. Dassa D; Lacambre M; Vacheron MN Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179 [No Abstract] [Full Text] [Related]
5. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Agid O; Foussias G; Remington G Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707 [TBL] [Abstract][Full Text] [Related]
6. Antipsychotic medication in the treatment of schizophrenia. Kane JM Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642 [TBL] [Abstract][Full Text] [Related]
7. Relapse prevention and recovery in the treatment of schizophrenia. Schooler NR J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093 [TBL] [Abstract][Full Text] [Related]
9. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Leucht S; Davis JM; Engel RR; Kissling W; Kane JM Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961 [TBL] [Abstract][Full Text] [Related]
10. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Current status of recommendations for treatment with an APAP]. Buis C; Gourion D; Vaiva G Encephale; 2009 Jan; Suppl 3():S91-5. PubMed ID: 19268185 [No Abstract] [Full Text] [Related]
11. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series. Deutschman DA; Deutschman DH J Clin Psychopharmacol; 2007 Oct; 27(5):513-4. PubMed ID: 17873687 [No Abstract] [Full Text] [Related]
12. Maintenance therapy and the natural course of schizophrenia. Davis JM J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252 [TBL] [Abstract][Full Text] [Related]
13. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of Canadian psychiatry]. Stip E Encephale; 2009 Jan; Suppl 3():S115-8. PubMed ID: 19268180 [No Abstract] [Full Text] [Related]
14. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia. Levinson I; Levine S Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667 [No Abstract] [Full Text] [Related]
15. Monotherapy versus polypharmacy for hospitalized psychiatric patients. Strous RD; Lerner V Am J Psychiatry; 2005 Mar; 162(3):631-2; author reply 632-3. PubMed ID: 15741496 [No Abstract] [Full Text] [Related]